127 related articles for article (PubMed ID: 25470586)
1. Treatment strategy for hepatitis C: a dilemma for the payers and the providers.
Haque M; Zariat A
Am J Gastroenterol; 2014 Dec; 109(12):1953-4. PubMed ID: 25470586
[No Abstract] [Full Text] [Related]
2. The new hepatitis C virus bottleneck: Can delaying therapy be justified?
Simon TG; Chung RT
Hepatology; 2015 Sep; 62(3):666-7. PubMed ID: 26058922
[No Abstract] [Full Text] [Related]
3. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
Canary LA; Klevens RM; Holmberg SD
Ann Intern Med; 2015 Aug; 163(3):226-8. PubMed ID: 26121095
[No Abstract] [Full Text] [Related]
4. [Costs of modern treatment of chronic hepatitis C].
Stiefelhagen P; Sarrazin C
Med Monatsschr Pharm; 2015 Sep; 38(9):347-9. PubMed ID: 26731852
[No Abstract] [Full Text] [Related]
5. Economics of chronic hepatitis B and hepatitis C.
Rajendra A; Wong JB
J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
[TBL] [Abstract][Full Text] [Related]
6. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.
Rein DB; Borton J; Liffmann DK; Wittenborn JS
Hepatology; 2016 Apr; 63(4):1135-44. PubMed ID: 26707033
[TBL] [Abstract][Full Text] [Related]
7. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
Ooka K; Connolly JJ; Lim JK
Am J Gastroenterol; 2017 Jun; 112(6):828-832. PubMed ID: 28374816
[No Abstract] [Full Text] [Related]
8. Only just the beginning of the end of hepatitis C.
Lancet; 2014 Jan; 383(9914):281. PubMed ID: 24461110
[No Abstract] [Full Text] [Related]
9. Doing battle with HCV.
Fimmel CJ
Am J Gastroenterol; 2000 Mar; 95(3):582-3. PubMed ID: 10710043
[No Abstract] [Full Text] [Related]
10. It's time to end insurance restrictions on life-saving hepatitis C treatments.
Clary R
Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
[No Abstract] [Full Text] [Related]
11. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C: global ambition, national realities.
Lancet; 2016 May; 387(10032):1970. PubMed ID: 27203752
[No Abstract] [Full Text] [Related]
13. What price for a cure?
Taylor LE
R I Med J (2013); 2014 Jul; 97(7):16-8. PubMed ID: 25184174
[No Abstract] [Full Text] [Related]
14. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
16. Enforcement of Legal Remedies to Secure Hepatitis C Virus Treatment With Direct-Acting Antiviral Therapies in Correctional Facilities and Medicaid Programs.
Greenwald R; Waters P; Cayer S
Public Health Rep; 2020; 135(1_suppl):44S-49S. PubMed ID: 32735189
[No Abstract] [Full Text] [Related]
17. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Einecke D
MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
[No Abstract] [Full Text] [Related]
18. A Novel Strategy for Increasing Access to Treatment for Hepatitis C Virus Infection for Medicaid Beneficiaries.
Sood N; Ung D; Shankar A; Strom BL
Ann Intern Med; 2018 Jul; 169(2):118-119. PubMed ID: 29799973
[No Abstract] [Full Text] [Related]
19. The multidimensional burden of hepatitis C and its treatment: a case study.
Taylor-Young P; Hildebrandt E
Gastroenterol Nurs; 2009; 32(3):180-7. PubMed ID: 19506434
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
